SIRT1 and ovarian cancer: In particular, 15-deoxy-Δ12,14-prostaglandin J2 (15d-PGJ2) exhibits potent anticancer activity by inhibiting SIRT1, and it has been found that its derivatives (J11-C1 and J19) exhibit anticancer activity against ovarian cancer SKOV3 cells in ovarian tissues [70].